Cerevel Therapeutics will host a virtual R&D event from 10:00 to 11:30 a.m. ET. Presented in a live webcast format, Cerevel will discuss CVL-871, a dopamine D1/D5 receptor partial agonist in development for the treatment of dementia-related apathy, and provide an update on CVL-231, a muscarinic M4 positive allosteric modulator in development for the treatment of schizophrenia. This R&D event is one of a series of virtual webcasts dedicated to providing in-depth discussions on key portfolio programs. CVL-871 is currently being studied in a Phase 2a exploratory trial to evaluate the compound as a potential treatment for dementia-related apathy. Apathy is among the most common neuropsychiatric co-morbidities associated with dementia, is one of the strongest predictors of disease progression, and is associated with higher mortality risk and early institutionalization. During todays discussion, key members of Cerevels scientific and clinical teams will be joined by Dr. Krista Lanctot, Professor of Psychiatry and Pharmacology/Toxicology at the University of Toronto, a leading expert in the neuropsychiatric manifestations of dementia, including apathy. Cerevel received Fast Track designation for the development of CVL-871 in this indication from the U.S. Food and Drug Administration earlier this year. Data from the ongoing Phase 2a trial are expected in the second half of 2022. CVL-231 is in development as a potential treatment for schizophrenia. In June, Cerevel announced positive topline results from its Phase 1b trial of CVL-231 and plans to initiate a comprehensive Phase 2 development program. Cerevel also intends to explore CVL-231 for other populations, including dementia-related psychosis. CVL-871 is a selective dopamine D1/D5 partial agonist specifically designed to achieve a level of partial agonism that is anticipated to modulate the complex neural networks that govern apathy-related behaviors in neurodegenerative diseases. In June 2021, Cerevel received Fast Track Designation from the U.S. Food and Drug Administration for CVL-871 for the treatment of dementia-related apathy. Cerevel began screening patients in an exploratory Phase 2a trial of CVL-871 for dementia-related apathy in the second quarter of 2021, with data expected in the second half of 2022. CVL-231 is a positive allosteric modulator designed to selectively target the M4 muscarinic receptor. M4 muscarinic receptors have been shown to influence the activation levels of acetylcholine, and subsequently, dopamine receptors, key neurotransmitter pathways in the brain that are known to be dysregulated in patients with schizophrenia. Topline results from a Phase 1b trial of CVL-231 in schizophrenia found both doses of the therapy demonstrated a clinically meaningful and statistically significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score at six weeks and were overall well-tolerated compared with placebo. Cerevel plans to advance CVL-231 to a comprehensive Phase 2 development program in schizophrenia and to evaluate the potential for this mechanism in other populations, including dementia-related psychosis.